CIRCLENCT07915505
Specific Immune Reconstitution After Allogeneic Transplantation and Letermovir Prophylaxis
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Eligibility criteria expanded, about 4 words
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Arms and interventions
CMV-seropositive hematopoietic stem cell transplant recipients receiving letermovir as primary prophylaxis and included in the NAViRe cohort. The study will describe overall and CMV-specific immune reconstitution, including its evolution during follow-up, using immunological and virological assessments.
Observational Cohort. CMV-seropositive hematopoietic stem cell transplant recipients included in the Cryostem cohort who did not receive letermovir as primary prophylaxis. The study will describe overall and CMV-specific immune reconstitution, including assessments before transplantation and at day 100 after transplantation.
Drugs: Letermovir
Other: Comparator
Sites
1 site in 1 country
- Chu LimogesLimoges, France